Terris M K, Peehl D M
Department of Urology, Stanford University Medical Center, California, USA.
Urology. 1997 Jul;50(1):150-6. doi: 10.1016/S0090-4295(97)00126-X.
Prior investigations evaluating the presence of human papillomavirus (HPV) in prostatic tissue by polymerase chain reaction (PCR) technology have yielded detection rates of 0% to 100%. Contamination by viral DNA from prostatic urethral colonization or less than optimal laboratory conditions have been suggested to explain this discrepancy. In addition, the various investigations have differed in the specific oligonucleotide primers utilized for amplification and, therefore, have searched for different segments of the viral genome. The objective of this study is to address these differences.
Forty-one archival radical prostatectomy specimens were evaluated, identifying areas of normal and abnormal histology. Meticulous technique was used during tissue acquisition, histologic confirmation, DNA isolation, PCR amplification, polyacrylamide gel electrophoresis, and staining. Primers for a 126- and 99-base pair (bp) fragment of the E6 portion of HPV 16 as well as a consensus primer for the L1 portion of the papillomavirus genome were utilized.
Of the normal prostatic tissues, 13.5% (5/37) contained the 126-bp E6 viral DNA as did 33.3% (7/21) of benign prostatic hyperplasia (BPH) samples, 25% (5/20) of dysplasia, 18.2% (2/11) of Gleason grades 1 and 2 adenocarcinoma, 25.9% (7/27) of Gleason grade 3 adenocarcinoma, and 6.7% (1/15) of Gleason grade 4 adenocarcinoma. Sections from the urethras of the prostatectomy specimens contained viral DNA in 31.7% (13/41). Viral detection was variable among different specimens in the same patient. With amplification for the 99-bp fragment of HPV 16, 1 of 37 normal (2.7%), 2 of 21 BPH (9.5%), 1 of 20 dysplasia (5.0%), and 2 of 53 cancer (3.8%) specimens revealed HPV DNA. In none of the specimens was DNA amplified using primers for a 450-bp fragment of the L1 portion of HPV.
Previously published discrepancies in HPV detection may be solely due to the differences in primer sets utilized.
先前通过聚合酶链反应（PCR）技术评估前列腺组织中人类乳头瘤病毒（HPV）存在情况的研究，其检测率在0%至100%之间。有人提出，前列腺尿道定植的病毒DNA污染或不太理想的实验室条件可解释这种差异。此外，各项研究在用于扩增的特定寡核苷酸引物方面存在差异，因此，所搜索的病毒基因组片段也不同。本研究的目的是解决这些差异。
对41份存档的根治性前列腺切除术标本进行评估，确定正常和异常组织学区域。在组织采集、组织学确认、DNA分离、PCR扩增、聚丙烯酰胺凝胶电泳和染色过程中采用了精细技术。使用了针对HPV 16 E6部分126个碱基对（bp）片段的引物以及针对乳头瘤病毒基因组L1部分的通用引物。
在正常前列腺组织中，13.5%（5/37）含有126 bp的E6病毒DNA，良性前列腺增生（BPH）样本中有33.3%（7/21）、发育异常中有25%（5/20）、Gleason 1级和2级腺癌中有18.2%（2/11）、Gleason 3级腺癌中有25.9%（7/27）、Gleason 4级腺癌中有6.7%（1/15）含有该病毒DNA。前列腺切除术标本尿道部分的切片中有31.7%（13/41）含有病毒DNA。同一患者不同标本中的病毒检测结果存在差异。用HPV 16的99 bp片段进行扩增时，37份正常标本中有1份（2.7%）、21份BPH标本中有2份（9.5%）、20份发育异常标本中有1份（5.0%）、53份癌症标本中有2份（3.8%）检测到HPV DNA。使用针对HPV L1部分450 bp片段的引物时，所有标本均未扩增出DNA。
先前发表的HPV检测差异可能完全是由于所用引物组的不同。
